Counteractive Effects of Diarylpropionitrile on Testosterone-Induced Benign Prostatic Hyperplasia in Rats via Targeting Key Androgenic, Angiogenic, Proliferative, and Inflammatory Mechanisms.

Ahmed Khalafa Ali¹, Ahmed Rahmah Abu-Raghif², Hayder Ridha-Salman^3,4

¹Department of Pharmacology, Al-Nahrain University College of Medicine, Baghdad, Iraq.

²Department of Pharmacology, Al-Nahrain University, Baghdad, Iraq.

³Pharmacology, Al-Mustaqbal University College of Pharmacy, Hillah, Iraq.

⁴Al-QasimGeneral Hospital, Babylon Health Directorate, Ministry of Health Iraq, Hillah,Babylon, Iraq.

PubMed DOI

Abstract

Benign prostatic hyperplasia is a common public health problem in aging men across the globe. Diarylpropionitrile, a selective estrogen receptor-beta agonist, favorably regulates cell proliferation and inflammation, two major hallmarks of benign prostatic hyperplasia pathology.This study aimed to explore the mitigative impact of diarylpropionitrile on testosterone-induced benign prostatic hyperpla…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.